AbCellera Biologics (ABCL) shares climbed as high as 10.3% to $6.53 during trading on August 7 before ending the session up 6.13%, as investors reacted to second-quarter results and an upcoming clinical catalyst.

The biotechnology company said it will release top-line Phase 2 data for ABCL635, its non-hormonal menopause treatment candidate, before the market opens on August 10, 2026. Management will also hold an investor conference call and webcast at 4:30 a.m. Pacific Time that day.

ABCL635 is described as a potentially first-in-class non-hormonal antibody approach targeting the NK3 receptor. The therapy is intended to reduce both the frequency and intensity of vasomotor symptoms in postmenopausal women. AbCellera said the program entered human trials in July 2025. The NK3 receptor has drawn increasing attention as a validated target for VMS since the FDA's 2023 approval of Astellas's fezolinetant (Veozah), a small-molecule NK3 antagonist, underscoring demand for non-hormonal options among women who cannot or prefer not to use hormone therapy.

AbCellera posted the announcement on X, writing: “AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 pic.twitter.com/haJhACRwFq — AbCellera (@AbCelleraBio) August 7, 2026”

The Phase 2 study enrolled about 80 postmenopausal participants in a randomized, double-blind, placebo-controlled design. The trial is registered under identifier NCT07118891.

The upcoming release will mark AbCellera’s first Phase 2 readout from its GPCR and ion channel discovery platform, making it an important milestone for the company. AbCellera has historically generated revenue through drug-discovery partnerships rather than proprietary clinical assets, so the ABCL635 readout is closely watched as a test of whether its platform can produce internally developed candidates that advance through mid-stage trials.

Second-quarter results show continued pressure

AbCellera’s second-quarter financial results reflected ongoing weakness. Revenue fell 76.3% year over year to $4.05 million, compared with $17.08 million in the same period of 2025. Net loss widened 59.7% to $55.4 million.

Basic loss per share came to $0.18, versus a loss of $0.12 per share a year earlier. Research and development spending totaled roughly $46 million during the quarter.

Even so, the company said its development pipeline continued to advance. AbCellera now has nine programs in Phase 1 and one in Phase 2, compared with 11 Phase 1 candidates and no Phase 2 assets at the same point last year.

ABCL575 has completed Phase 1 dose escalation, and top-line data are expected in the fourth quarter of 2026.

Liquidity remains a bright spot

Despite ongoing operating losses, AbCellera ended the quarter with $567 million in cash and cash equivalents and more than $675 million in total available liquidity.

The company also said strategic collaborations with Jazz Pharmaceuticals and Vertex, focused on T cell engager development programs, generated more than $110 million in upfront payments.

Some observers note that these payments are one-time transaction proceeds rather than recurring revenue. Milestone payments and royalty income have not yet reached levels sufficient to offset operating deficits.

The latest analyst coverage on ABCL carries a Buy rating and a $12.00 price target. AbCellera’s market capitalization is currently about $1.74 billion.

Investor attention now turns to the August 10 data readout for ABCL635.